Spectrum Pharmaceuticals is a leading global biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in oncology and hematology. Spectrum and its affiliates market three oncology drugs: FUSILEV® for Injection in the U.S.; FOLOTYN®, which is also marketed in the U.S.; and ZEVALIN® Injection for intravenous use, for which the company has worldwide marketing rights. Spectrum also provides medical education grants and sponsorships to qualified individuals. For more information, visit the company’s Web site at www.sppirx.com.